Sign In
Buy ICAD
$3.87
+0 (+0%)
At Close: Oct 16, 2025
iCAD Announces FDA Clearance for ProFound AI Version 3.0 for 3D Mammography
06:04pm, Monday, 15'th Mar 2021
Company's third generation AI solution offers significant improvement in algorithm specificity performance and faster processing compared to previous versions of the software
New Research Supporting ProFound AI Presented at European Congress of Radiology Online Meeting
12:36pm, Monday, 08'th Mar 2021
Company showcased expanded ProFound AI platform, including ProFound AI Risk, the world's first clinical decision support tool that provides a highly accurate short-term risk estimation specific to eac
Icad (ICAD) Soars 8.5%: Is Further Upside Left in the Stock?
07:36am, Thursday, 04'th Mar 2021
Icad (ICAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
iCAD to Participate in the Cowen 41st Annual Health Care Conference
09:16pm, Wednesday, 03'rd Mar 2021
NASHUA, N.H., March 03, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael
iCAD Announces Pricing of $22.0 Million Public Offering of Common Stock
12:47am, Wednesday, 03'rd Mar 2021
NASHUA, N.H., March 03, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today ann
iCAD (ICAD) in Focus: Stock Moves 7.6% Higher
09:52am, Monday, 01'st Mar 2021
iCAD (ICAD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
iCAD's (ICAD) CEO Michael Klein on Q4 2020 Results - Earnings Call Transcript
01:57am, Thursday, 25'th Feb 2021
iCAD's (ICAD) CEO Michael Klein on Q4 2020 Results - Earnings Call Transcript
Icad (ICAD) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Wednesday, 24'th Feb 2021
Icad (ICAD) delivered earnings and revenue surprises of 25.00% and 30.64%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2020
04:01pm, Wednesday, 24'th Feb 2021
Fourth Quarter Revenues of $10.5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI® Product Revenue
iCAD's (ICAD) Shares March Higher, Can It Continue?
11:20am, Thursday, 11'th Feb 2021
As of late, it has definitely been a great time to be an investor in iCAD, Inc. (ICAD).
iCAD to Participate in B. Riley Securities Virtual Oncology Investor Conference
08:00am, Tuesday, 19'th Jan 2021
NASHUA, N.H., Jan. 19, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael
iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
04:01pm, Wednesday, 06'th Jan 2021
New ProFound AI risk software, offering a 2-year projected risk score to be featured New ProFound AI risk software, offering a 2-year projected risk score to be featured
International Multi-Center Study to Commence January 2021
Solis Mammography Adopts iCAD's ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution
08:00am, Thursday, 10'th Dec 2020
Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services' Network Agreement Positions Bot
iCAD Highlights Expanded Suite of Leading Breast Health AI Solutions at Virtual RSNA 2020
08:00am, Monday, 30'th Nov 2020
Groundbreaking ProFound AI Risk Helps Transform Breast Cancer Screening from an Age-Based Paradigm to Risk-Adapted Precision Screening, Individualized for Each Woman Groundbreaking ProFound AI Risk He
